-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON SUBMITS APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR TECVAYLI®▼ (TECLISTAMAB) IN COMBINATION WITH DARZALEX® (DARATUMUMAB) SUBCUTANEOUS FORMULATION FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

路透·01/06/2026 13:08:59

登錄查看新聞詳情